CN110656165B - Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication - Google Patents
Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication Download PDFInfo
- Publication number
- CN110656165B CN110656165B CN201910858799.0A CN201910858799A CN110656165B CN 110656165 B CN110656165 B CN 110656165B CN 201910858799 A CN201910858799 A CN 201910858799A CN 110656165 B CN110656165 B CN 110656165B
- Authority
- CN
- China
- Prior art keywords
- seq
- primer
- extension
- pcr
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
The invention discloses a gene SNP detection kit for determining clopidogrel medication curative effect correlation, which comprises a MassARRAY chip, rs16863356, rs7634096 and rs12497330 for detecting gene P2Y12, wherein three primers of 3 SNP loci are respectively called as a forward primer, a reverse primer and an extension primer, the sequences of the primers are respectively shown as SEQ ID No. 1-9, and the primers are polymorphic loci for identifying clopidogrel drug effect and adverse reaction correlation genes. The kit can carry out high-throughput detection on the three sites, and has the advantages of high sensitivity, high specificity, stable detection result, high reliability and the like; meanwhile, the method is suitable for the gene analysis fields of clinical disease mutation detection, pharmacogenomics analysis, forensic medicine identification and the like.
Description
Technical Field
The invention belongs to the technical field of genes, and relates to a detection kit for determining gene polymorphism (SNP) related to the therapeutic effect of clopidogrel administration.
Background
Clopidogrel (Clopidogrel) is chemically (S) -alpha- (2-chlorophenyl) -6, 7-dihydrothieno [3, 2-C)]Pyridine-5 (4H) -acetic acid methyl ester, formula C16H16ClNO2And S. Clopidogrel is a novel and widely used first-choice medicament for treating cardiovascular and cerebrovascular diseases, particularly acute coronary syndrome and percutaneous coronary intervention. Meanwhile, clopidogrel has certain characteristics on the structural characteristics and functions as a thienopyridine antiplatelet medicament, and clinical adverse events have certain advantages compared with other anticoagulants, so the clopidogrel is considered as the antiplatelet medicament which is considered to be important in the treatment process of cardiovascular and cerebrovascular diseases. In recent years, intensive research and clinical observation show that adverse clinical events still exist in the anti-platelet treatment of patients with cardiovascular and cerebrovascular diseases after receiving regular clopidogrel medication, wherein the most common clinical events comprise myocardial infarction, cerebral apoplexy, thrombus in a stent, even death and the like.
Cardiovascular and cerebrovascular diseases are relatively complex chronic diseases, which are the result of interaction of non-genetic factors (age, height, weight, interaction of drugs, dietary habits and the like) such as environmental factors and a plurality of factors such as genetic factors, wherein the genetic factors play a core leading role in the process to cause individual differences, and the individual differences are gene mutations of proteins or enzymes related to pharmacokinetics and pharmacodynamics of clopidogrel, effective protein expression and enzyme activity, so that the curative effect of clopidogrel is enhanced or reduced. Therefore, in order to achieve the optimal treatment effect of the drug, namely, to improve the drug effectiveness or reduce the occurrence of adverse drug reactions, the deep excavation of the drug effect of the clopidogrel and the biomarkers related to the adverse reactions is more and more important, and the social health problem to be solved is also formed.
The clopidogrel is firstly absorbed by oral administration into intestinal tracts, the whole process is accompanied with P-glycoprotein (ABCB1 gene coding) transportation, the finally activated metabolite is directionally selected to a certain extent to be directly and irreversibly combined with a platelet surface ADP receptor P2Y12 by utilizing the activation effect of cytochrome enzyme CYP450, so that the aim of blocking the activity enhancement effect of platelets is fulfilled, the subsequent activation of ADP mediated GP IIb/IIIa compound is further inhibited, and the activation and aggregation of the platelets are finally inhibited. In the search of the existing literature, the P2Y12 gene is located on the human chromosome 3 q25.1 and is used as the final binding receptor in the clopidogrel metabolic process, namely the polymorphism of the drug target P2Y12 gene, but the related reports that P2Y12 rs16863356, rs7634096 and rs12497330 are clopidogrel drug effect molecular markers are not found in China before.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a gene SNP detection kit for determining the related curative effect of clopidogrel medication; in particular to a method for detecting 3 gene polymorphic sites of P2Y12 gene related to therapeutic effect and adverse reaction of clopidogrel drugs by utilizing a multiplex PCR technology, a single base extension technology and a mass spectrum technology and a corresponding kit.
The purpose of the invention is realized by the following technical scheme,
in a first aspect, the present invention relates to a primer set for detecting a gene polymorphism site related to clopidogrel medication efficacy, comprising:
detecting a PCR primer with the sequence of rs16863356 shown as SEQ ID No. 2 and SEQ ID No. 5 and an extension primer with the sequence shown as SEQ ID No. 8 in the peripheral blood DNA;
detecting a PCR primer with the sequence of rs7634096 shown as SEQ ID No.1 and SEQ ID No. 4 and an extension primer with the sequence shown as SEQ ID No. 7 in peripheral blood DNA;
detecting the PCR primer with the sequence of rs12497330 in the peripheral blood DNA as shown in SEQ ID No. 3 and SEQ ID No. 6 and the extension primer with the sequence as shown in SEQ ID No. 9.
The corresponding molecular weights of the extension primers and the extension primers at each site are shown in table 1 below:
| extension primer | Site of the body | Molecular weight of extended primer |
| SEQ ID No:7 | rs7634096 | 6106 |
| SEQ ID No:8 | rs16863356 | 7369.8 |
| SEQ ID No:9 | rs12497330 | 8526.6 |
The primer is designed on a gene typing MassARRAY platform, and is more efficient, accurate and high-flux compared with the prior art.
In a second aspect, the invention relates to a kit for SNP detection of related genes of clopidogrel personalized medicine, which comprises the primer set.
As one embodiment of the kit, the kit further comprises a detection reagent, a detection chip and a detection carrier.
The detection reagent comprises a PCR mixed reaction solution, an SAP enzyme mix reaction solution and a UEP extension mix reaction solution.
As an embodiment of the kit, the kit also comprises a resin for purification, a target sheet for spotting and mass spectrometry and a human genome DNA extraction reagent.
In a third aspect, the invention also relates to a non-diagnostic purpose use method of the kit for carrying out SNP detection on related genes of clopidogrel personalized medication, which comprises the following steps:
s1, performing PCR primer dilution and UEP extension primer dilution by using the primer group;
s2, PCR reaction;
s3, SAP digestion reaction;
s4, UEP extension reaction;
s5, purifying resin.
In step S2, the PCR mixed reaction solution adopted in the PCR reaction includes deionized water, PCR Buffer, MgCl2, dNTPs, thermostable Taq DNA polymerase, and amplification primer mix.
In step S3, the SAP enzyme mix reaction solution used in the SAP digestion reaction includes deionized water, SAP Buffer, and SAP enzyme.
In step S4, the UEP extension mix reaction solution used in the UEP extension reaction includes deionized water, Gold Buffer, Termination mix, UEP primer mix, and high temperature resistant extension enzyme.
In step S5, the resin for purification is dropped into the single-base-charged extension product obtained in step S4.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention integrates the technologies of multiplex PCR, single base extension, mass spectrum detection and the like, can detect trace samples while amplifying a detection template, and has very high detection sensitivity;
2. single base extension is also called micro sequencing, and uses a specific probe to identify DNA, so that the method has the advantages of good specificity, low false positive and the like;
3. the high-throughput sequencing technology has high speed and high efficiency, and can complete hundreds of sample detections in 3-4 hours;
4. the operation is simple, and meanwhile, the pollution is reduced under the automatic operation;
5. the invention can detect a plurality of patients and can obtain different gene locus information at the same time;
6. the invention overcomes the defect of high cost of detecting a small amount of SNP loci at one time in the prior art;
7. the invention lays a foundation for researching the relation between the polymorphism of the P2Y12 gene of the population in China and the safety of clinical medication, provides a theoretical basis for clinical individualized medication, and provides a guiding basis for the research and development of new drugs based on the pharmacogenomics concept.
Detailed Description
The present invention will be described in detail with reference to examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that it would be apparent to those skilled in the art that several modifications and improvements can be made without departing from the inventive concept. All falling within the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally following conventional conditions, such as molecular cloning by Sambrook et al: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1: primer design and Synthesis
Aiming at 3 gene polymorphic sites related to clopidogrel medication at the sites rs16863356, rs7634096 and rs12497330 of the P2Y12 gene, designing corresponding specific PCR primer sequences (SEQ ID No:1 to SEQ ID No:6) and specific extension primer sequences (SEQ ID No:7 to SEQ ID No: 9); specifically, as shown in Table 2:
TABLE 2
| Numbering | Targeting sites | Sequence (5'-3') | Use of |
| SEQ ID No:1 | rs7634096 | ACGTTGGATGTAAAATAGGTCCTCAGACCC | PCR forward primer |
| SEQ ID No:2 | rs16863356 | ACGTTGGATGTGAGTCTTAGCAACTGAAGG | PCR forward primer |
| SEQ ID No:3 | rs12497330 | ACGTTGGATGCACTTTATATACATACCCTG | PCR forward primer |
| SEQ ID No:4 | rs7634096 | ACGTTGGATGCATCCCTGTCTCTCACAAAG | PCR reverse primer |
| SEQ ID No:5 | rs16863356 | ACGTTGGATGACAAGTGTGTCAGGAATACC | PCR reverse primer |
| SEQ ID No:6 | rs12497330 | ACGTTGGATGCACAGTCAAAATGTAGACAC | PCR reverse primer |
| SEQ ID No:7 | rs7634096 | ACAGGGTTGTTTTGCCTTCT | Extension primer |
| SEQ ID No:8 | rs16863356 | TGTATCAGGAATACCAATACTGAA | Extension primer |
| SEQ ID No:9 | rs12497330 | CCCTGAAGGTAATTTTATTTTTCTCTTG | Extension primer |
Example 2 sample DNA extraction
The extracted 5ml blood was collected in a vacuum blood collection tube containing 3.2% trisodium citrate and lithium heparin, and left to stand for at least 6 hours. The tube was inverted 3-5 times to ensure adequate mixing of the blood with the anticoagulant. By using
DNA extraction is carried out by a DNA Mini Kit (250) Kit; the DNA concentration is measured in a Saimerfi NanoDrop 2000 ultramicro ultraviolet spectrophotometer; when the sample is measured, it needs to be recordedRecording three values of concentration, 260/280 and 260/230 so that the concentration does not reach the requirement of searching possible pollution causes, and simultaneously requiring that an experimenter needs to subpackage DNA samples so as to reduce the times of sample freeze thawing in the experimental process and ensure the high quality of DNA. And then diluting the extracted sample to 10-20 ng/mu L by using deionized water so as to meet the basic requirement of quality control of a subsequent genotyping sample.
Example 3 biological experiments
Detecting 3 gene polymorphisms related to the drug effect of clopidogrel according to an instruction by using an ABI 9700 type PCR instrument; the reagents involved are shown in table 3:
TABLE 3
1. And (3) PCR reaction conditions: at 95 ℃ for 2 min; 45 cycles (95 ℃, 30 s; 56 ℃, 30 s; 72 ℃, 60 s); 72 ℃ for 5 min.
2. SAP digestion reaction conditions: at 37 ℃ for 40 min; 85 ℃ for 5 min.
3. UEP extension reaction conditions: 30s at 94 ℃; 40 external cycles (94 ℃, 5 s; 5 internal cycles (52 ℃, 5 s; 80 ℃, 5 s)); 72 ℃ for 3 min.
4. And (3) purification: add 16. mu.L of DI water to each tube extension, add MassARRAY kit resin until well mixed and centrifuge.
5. Sample application: using a micropipette, 1. mu.L of the purified product was spotted onto the target slide.
6. And (3) computer detection: 24 needles of the sample application mechanical arm are cleaned by NaOH; sample application; and (4) detecting by mass spectrometry.
P2Y12(rs16863356, rs7634096, rs12497330) was found to have significant individual differences from NPR (normal platelet activity) by analysis (table 4).
TABLE 4
| Gene | SNP | Allele | OR(95％CI) | P | 2 | |
| P2Y12 | rs16863356 | A | G | 0.584(0.375-0.909) | 0.016 | 5.769 |
| HPR,n(％) | 37(13.70) | 233(96.30) | ||||
| NPR,n(％) | 65(21.38) | 239(78.62) | ||||
| P2Y12 | rs7634096 | T | C | 0.592(0.383-0.915) | 0.017 | 5.646 |
| HPR,n(％) | 39(14.55) | 229(85.45) | ||||
| NPR,n(％) | 67(22.33) | 233(77.67) | ||||
| P2Y12 | rs12497330 | A | G | 0.497(0.333-0.742) | 0.00056 | 11.9 |
| HPR,n(％) | 105(0.625) | 63(0.375) |
As can be seen, the individual differences of the three SNP loci rs16863356, rs7634096 and rs12497330 in the patients with clopidogrel medication are obvious in P2Y 12.
In conclusion, the invention provides theoretical and prognostic foundation for P2Y12 gene polymorphism and clinical guidance medication in cardiovascular and cerebrovascular populations in China, and lays a genetic foundation for individualized pharmacogenomics.
The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.
Sequence listing
<110> Shanghai university of transportation
<120> gene SNP detection kit for determining clopidogrel medication curative effect correlation
<130> DAG41295
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
acgttggatg taaaataggt cctcagaccc 30
<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
acgttggatg tgagtcttag caactgaagg 30
<210> 3
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
acgttggatg cactttatat acataccctg 30
<210> 4
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
acgttggatg catccctgtc tctcacaaag 30
<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
acgttggatg acaagtgtgt caggaatacc 30
<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
acgttggatg cacagtcaaa atgtagacac 30
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
acagggttgt tttgccttct 20
<210> 8
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
tgtatcagga ataccaatac tgaa 24
<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
ccctgaaggt aattttattt ttctcttg 28
Claims (10)
1. A primer group for detecting gene polymorphism sites related to clopidogrel medication curative effect comprises:
detecting a PCR primer with the sequence of rs16863356 shown as SEQ ID No. 2 and SEQ ID No. 5 and an extension primer with the sequence shown as SEQ ID No. 8 in the peripheral blood DNA;
detecting a PCR primer with the sequence of rs7634096 shown as SEQ ID No.1 and SEQ ID No. 4 and an extension primer with the sequence shown as SEQ ID No. 7 in peripheral blood DNA;
detecting the PCR primer with the sequence of rs12497330 as shown in SEQ ID No. 3 and SEQ ID No. 6 and the extension primer with the sequence as shown in SEQ ID No. 9 in the peripheral blood DNA;
the molecular weights of the extension primers and the extension primers corresponding to each site are as follows:
。
2. A kit for SNP detection of related genes of clopidogrel personalized medicine, comprising the primer set of claim 1.
3. The kit of claim 2, further comprising a detection reagent, a detection chip, and a detection carrier.
4. The kit of claim 3, wherein the detection reagents comprise a PCR mix reaction, an SAP enzyme mix reaction, and a UEP extension mix reaction.
5. The kit of claim 3, further comprising a resin for purification, a target for spotting and mass spectrometric detection, and a human genomic DNA extraction reagent.
6. A method for using the kit for SNP detection of clopidogrel personalized medicine related genes according to claim 2 for non-diagnostic purposes, characterized in that it comprises the following steps:
s1, performing PCR primer dilution and UEP extension primer dilution by using the primer group;
s2, PCR reaction;
s3, SAP digestion reaction;
s4, UEP extension reaction;
s5, purifying resin.
7. The use of the method according to claim 6, wherein in step S2, the PCR mixture solution used in the PCR reaction comprises deionized water, PCR Buffer, MgCl2, dNTPs, heat-resistant Taq DNA polymerase, and amplification primers mix.
8. The use of claim 6, wherein in step S3, the SAP digestion reaction uses an SAP enzyme mix reaction solution comprising deionized water, SAP Buffer, and SAP enzyme.
9. The use method according to claim 6, wherein in step S4, the UEP extension reaction uses UEP extension mix reaction solution containing deionized water, Gold Buffer, Termination mix, UEP primer mix and high temperature resistant extension enzyme.
10. The use of claim 6, wherein in step S5, the purification resin is dropped into the single base extension product obtained in step S4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910858799.0A CN110656165B (en) | 2019-09-11 | 2019-09-11 | Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910858799.0A CN110656165B (en) | 2019-09-11 | 2019-09-11 | Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110656165A CN110656165A (en) | 2020-01-07 |
| CN110656165B true CN110656165B (en) | 2020-11-17 |
Family
ID=69037152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910858799.0A Active CN110656165B (en) | 2019-09-11 | 2019-09-11 | Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110656165B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107904306B (en) * | 2018-01-08 | 2021-03-30 | 厦门基源医学检验实验室有限公司 | Nucleic acid mass spectrum detection kit for detecting clopidogrel personalized medication related gene polymorphism sites and application |
-
2019
- 2019-09-11 CN CN201910858799.0A patent/CN110656165B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110656165A (en) | 2020-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2707498B1 (en) | Method for discovering pharmacogenomic biomarkers | |
| CN108486231A (en) | Primer combination of probe object, kit and application for detecting mankind's CYP2C19 gene pleiomorphisms | |
| CN106701987A (en) | PCR (polymerase chain reaction) amplification system for genotyping of three SNP (single-nucleotide polymorphism) loci related to human folic acid metabolism and detection kit | |
| CN106498035A (en) | A kind of construction method and its application for detecting chemotherapeutics gene SNP variation library for high-flux sequence | |
| CN106498036A (en) | A kind of construction method in the Drug Discovery SNP variations library for high-flux sequence detection and its application | |
| CN105886606A (en) | Kit for rapid detection of polymorphism of Warfarin metabolic enzyme gene by virtue of pyrosequencing method and application of kit | |
| CN110699446B (en) | SNP marker rs3174298 related to non-syndrome cleft lip and palate diagnosis and application thereof | |
| CN110699440A (en) | Primer and method for detecting SNP (single nucleotide polymorphism) locus of gene related to metformin personalized medicine | |
| CN109097459B (en) | Detection method for adult common anti-infective drug administration analysis based on SNP locus and application thereof | |
| CN114427001A (en) | Kit for evaluating effectiveness of adalimumab in treating psoriasis based on 78 SNP loci | |
| CN110656165B (en) | Gene SNP detection kit for determining related therapeutic effect of clopidogrel medication | |
| CN108949967B (en) | Specific primer and kit for detecting cardiovascular disease drug gene polymorphism by liquid phase chip technology | |
| CN110499368A (en) | One kind SNP marker relevant to carcinoma of mouth prognosis prediction and its application | |
| CN103320531B (en) | A kind of novel method that simultaneously can detect multiple HBV resistant mutational site | |
| CN108531599A (en) | A kind of kit and method of people HLA-B*5801 genotype | |
| CN110564836A (en) | Primer-probe combination for guiding detection of related genes for repaglinide drug personalized administration, kit and application | |
| CN110484619A (en) | It is a kind of to detect clopidogrel drug effect kit using rs11249454 | |
| CN111235255A (en) | Method for distinguishing individual medication of nitrendipine by using primer composition through mass spectrometry | |
| CN111197078A (en) | Method for distinguishing nifedipine personalized medicine by mass spectrometry through product detection | |
| CN111197080A (en) | Detection product for distinguishing nifedipine individualized medication type | |
| CN110592206A (en) | Kit for detecting Huafa drug effect by using rs9934438 | |
| CN112695083B (en) | Nucleic acid composition and kit for detecting gene polymorphism of medicine for hypertension | |
| CN116445596B (en) | Product and method for human genotyping and application thereof | |
| CN111139295B (en) | SNP marker related to non-syndromic polyodontogenesis diagnosis and application thereof | |
| CN101463389A (en) | Multiple quantitative RT-PCR gene expression spectrum analysis method based on fluorescent universal primer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |